Instil Bio, Inc.

The company is a biotechnology enterprise focused on discovering, acquiring, and advancing innovative therapeutic candidates for conditions with significant unmet medical need. Its core operational strategy revolves around pursuing acquisitions and in-licensing opportunities for novel drug candidates rather than selling established commercial products. Historically, its research activities included cell therapies, specifically a proprietary folate receptor alpha co-stimulatory antigen receptor tumor-infiltrating lymphocyte therapy for cancer, alongside an in-licensed bispecific antibody candidate, AXN-2510, targeting solid tumor cancers. Because the enterprise operates as a clinical development entity without approved therapies, it has no commercial customer base.

The business operates through its wholly owned subsidiary, Axion Bio, Inc., which previously handled the in-licensing and development of its discontinued lead candidate. Its research aspirations and regulatory pursuits span the United States and potential international jurisdictions, but the provided text does not disclose physical facility counts, geographic footprints, or specific headquarters location details.

Summary of the business section of Instil Bio's latest annual report, written by StockData.

“As of December 31, 2025, we had 17 employees, all of whom were full-time.”